LY
Lyell Immunopharma, Inc.
LYEL · NASDAQ
$14.37 +0.56% (+$0.08)
1M +1.13%
Market Cap $350.9M
P/E Ratio -
Div. Yield -
ROE 91.62%
Piotroski F-Score Weak
1/9Valuation
50 /100
Fair P/S 12,996.40x
P/B 1.50x
P/E N/A
Growth
0 /100
Declining Rev. growth 92.48%
Book val. growth 33.22%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 8,537.04%
Net margin 920,285.00%
FCF margin 496,189.00%
Quality
0 /100
Poor ROIC 70.80%
ROE 91.62%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.16x
Current ratio 5.36x
Int. coverage N/A
Stability
21 /100
Unstable Beta -0.07x
Rev. volatility 31.09%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o LYEL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Lynn Seely
Employees
161
Headquarters
South San Francisco
Prihajajoči dogodki
10 NOV.
Earnings
Upcoming earnings report